LEVAFLUKE ORAL DRENCH.
Nchi: Ayalandi
Lugha: Kiingereza
Chanzo: HPRA (Health Products Regulatory Authority)
Tabia za bidhaa
(SPC)
06-06-2024
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
LEVAMISOLE HYDROCHLORIDE, RAFOXANIDE
Inapatikana kutoka:
Biochem Ltd
ATC kanuni:
QP52AE51
INN (Jina la Kimataifa):
LEVAMISOLE HYDROCHLORIDE, RAFOXANIDE
Kipimo:
Unknown
Dawa fomu:
Oral Suspension
Dawa ya aina:
LM-Licensed Merchant
Kundi la matibabu:
Bovine, Ovine
Eneo la matibabu:
Levamisole, combinations
Matibabu dalili:
Endoparasiticide
Idhini hali ya:
Authorised
Idhini ya tarehe:
1999-10-01
Tabia za bidhaa
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Levafluke Oral Drench.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients see section 6.1
3 PHARMACEUTICAL FORM
Oral Suspension.
A yellow aqueous suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_LEVAFLUKE _is a combination product for the treatment of the common nematode parasites (including lung worm -
_Dicytocaulus _spp.) and liver fluke (_Fasciola hepatica_) in cattle and sheep.
_Levafluke _is active against
_Fasciola hepatica, (mature and immature over 8 weeks of age)_
_Nematodirus spp.,_
_Dictyocaulus spp.,_
_Ostertagia spp. _in cattle and sheep (except inhibited ostertagia larvae)_._
4.3 CONTRAINDICATIONS
Do not use in concurrent treatment with organophosphates and/or diethylcarbamazine.
Do not use in animals with known hypersensitivity to the active ingredients.
ACTIVE SUBSTANCE
QUANTITY PER ML
Rafoxanide
22.5 mg
Levamisole Hydrochloride
15.0 mg
EXCIPIENTS
Methyl Parahydroxybenzoate (E218) 1.0 mg
Propyl Parahydroxybenzoate (E216) 0.1 mg
Sodium metabisulphite (E223)
0.2 mg
Quinoline yellow (E104)
0.09 mg
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 16/04/2013_
_CRN 7014587_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could
ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration
of the dos
Soma hati kamili
